- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05714683
Estudio de vigilancia regulatoria posterior a la comercialización (rPMS) de Rybelsus (semaglutida oral) para evaluar la seguridad y la eficacia en pacientes con diabetes mellitus tipo 2 en la práctica clínica de rutina en Corea
Un estudio multicéntrico, prospectivo, abierto, de un solo brazo, no intervencionista, de vigilancia posterior a la comercialización (SPMr) de Rybelsus® (semaglutida oral) para evaluar la seguridad y la eficacia en pacientes con diabetes mellitus tipo 2 en la práctica clínica habitual en Corea
The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Novo Nordisk
- Número de teléfono: (+1) 866-867-7178
- Correo electrónico: clinicaltrials@novonordisk.com
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adult participants with T2DM, who initiate treatment with Rybelsus under routine clinical practice in Korea.
Descripción
Inclusion Criteria:
- The decision to initiate treatment with commercially available Rybelsus has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study
- The participant with T2DM is scheduled to start treatment with Rybelsus based on the clinical judgment of their treating physician as specified in the approved label in Korea
- Informed consent is obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
- Male/female age greater than or equal to (>=) 19 years at the time of signing informed consent
Exclusion Criteria:
- Participants who are or have previously been on Rybelsus therapy
- Known or suspected hypersensitivity to Rybelsus, the active substance or any of the excipients
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Female participant who is pregnant, breast-feeding or intends to become pregnant and is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by Korea regulation or practice)
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Family or personal history of multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary Thyroid Carcinoma (MTC)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Participants with T2DM
All participants will be treated with Rybelsus for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by Ministry of Food and Drug Safety (MFDS). |
All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number (Incidence) of adverse events (AEs)
Periodo de tiempo: From baseline (week 0) to 26 weeks
|
Measured as count of events. |
From baseline (week 0) to 26 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number (Incidence) of hypoglycaemia Level 3 or Level 2
Periodo de tiempo: From baseline (week 0) to 26 weeks
|
Hypoglycaemia Level 3 or Level 2 according to American Diabetes Association (ADA) guideline 2020 refers to: 1) Level 2: Glucose less than (<) 54 milligrams per deciliter (mg/dL) (3.0 millimoles per liter [mmol/L]); 2) Level 3: A severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycaemia. Measured as count of events. |
From baseline (week 0) to 26 weeks
|
|
Change in glycated haemoglobin (HbA1c)
Periodo de tiempo: From baseline (week 0) to 26 weeks
|
Measured in percentage (%). |
From baseline (week 0) to 26 weeks
|
|
Participants achieving HbA1c target <7.0%
Periodo de tiempo: At 26 weeks
|
Measured as count of participants (Yes/No). |
At 26 weeks
|
|
Change in fasting blood glucose (FBG)/fasting plasma glucose (FPG)
Periodo de tiempo: From baseline (week 0) to 26 weeks
|
Measured in mg/dL. |
From baseline (week 0) to 26 weeks
|
|
Change in post prandial blood glucose (PPBG)/post prandial plasma glucose (PPPG)
Periodo de tiempo: From baseline (week 0) to 26 weeks
|
Measured in mg/dL. |
From baseline (week 0) to 26 weeks
|
|
Change in body weight
Periodo de tiempo: From baseline (week 0) to 26 weeks
|
Measured in kilogram (kg). |
From baseline (week 0) to 26 weeks
|
|
Dose of Rybelsus
Periodo de tiempo: At 26 weeks
|
Measured in milligrams per day (mg/day). |
At 26 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- NN9924-4652
- U1111-1243-9500 (Otro identificador: World Health Organization (WHO))
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .